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Abstract: Lipodystrophy remains a major long-term complication in human immunodeficiency 
virus-infected patients under antiretroviral (ARV) therapy. Patients may present with lipoatrophy 
or lipohypertrophy or both. The choice of treatments to improve fat redistribution depends on 
the form of lipodystrophy and its duration. Measures known to improve lipoatrophy are switches 
in ARV therapy (stavudine or zidovudine to abacavir or tenofovir) and filling interventions. 
Pioglitazone may be added to these measures, although any benefits appear small. Uridine and 
leptin were found to be disappointing so far. Regarding lipohypertrophy, diet and exercise, 
recombinant human growth hormone, and metformin may reduce visceral fat, but may worsen 
subcutaneous lipoatrophy. Surgical therapy may be required. Attractive pharmacologic treatments 
include growth hormone-releasing factor and leptin. Adiponectin and adiponectin receptors are 
promising therapeutic targets to explore.
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Introduction
Lipodystrophy remains a major concern for human immunodeficiency virus (HIV)-
infected patients, although its incidence tends to decrease with the use of new 
antiretroviral (ARV) combinations. The negative impact of lipodystrophy on quality 
of life of patients, sexual function, and adherence to ARV treatment has been widely 
documented.1–9
Management of lipodystrophy includes ARV switch strategies, lifestyle modifica-
tions, pharmacologic interventions, and surgical or cosmetic corrective treatments.
After a few reminders on the definition, incidence, pathogenesis, and diagnosis of 
lipodystrophy, this review will focus on new and emerging therapeutic strategies.
Definition
Lipodystrophy includes fat loss (lipoatrophy) and fat accumulation (lipohypertrophy), 
which may exist separately or be combined (mixed syndrome) in a single patient. 
Despite some anthropometric measurements and/or imaging could detect fat mass 
changes earlier than physical examination, the current definition and classification are 
based on the patients’ self-assessment confirmed by the physician during a detailed 
physical examination.10
Lipoatrophy occurs on the face, the buttocks, the arms, and the legs, whereas lipohy-
pertrophy may be revealed by abdominal obesity, mammary hypertrophy, accumulation 
of fat on the neck or the suprapubic region, and localized or generalized lipoma.
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A diagnosis model including demographic, clinical, 
biological, and radiological parameters has been proposed 
by Carr et al.11 This model has a sensitivity of 79% and 
a specificity of 80%;12 however, its complexity makes it 
impractical for routine use.
Incidence
The overall prevalence of lipodystrophy remains high in 
HIV-infected patients upon ARV treatment. The incidence 
of lipoatrophy is still high in countries where thymidine 
analogs (stavudine and to a lesser extent zidovudine) 
are frequently prescribed.13–16 Because standardized criteria 
for the definition of lipodystrophy are lacking, the frequency 
of lipodystrophy observed in major clinical studies varies 
from 2% to 84%, with a mean prevalence of 40%–60%.17–22 
The significant variations found among different studies 
may also be explained by the composition of the populations 
(different gender, age, race, or ethnicity), the ARV used, and 
the duration of observation.
The prevalence of lipoatrophy is also widely variable, 
from 13% to 67%.23–28 It has been estimated that 16%–29% 
of patients present lipoatrophy after 3 years of ARV 
treatment.29,30 However, these studies have been conducted in 
the late 90s and early 2000s, and the regimens have evolved. 
Besides, some recent studies that have evaluated new drug 
combinations suggest lower incidence.
Differences in frequency of lipoaccumulation reported 
throughout various studies are even more important, from 6% 
(in men) to 93% (in women).23–28 Once again wide variations 
may be explained by the definition criteria used, populations 
studied, and the duration of observation.
The prevalence of mixed syndrome has been found to 
range from 20% to 29%.23,24,26–28 The prevalence reported at 
3 years has varied from 8% to 12.5%.30,31
Pathogenesis and risk factors
The pathogenesis of lipoatrophy and lipohypertrophy is 
multifactorial, and common risk factors have been identified 
as the patient, HIV infection, and ARV drugs.32–35
Potential host risk factors include age, sex, race, or 
ethnicity.22,29,36,37 Genetic components have also been 
reported. Lipodystrophy is more common in older patients. 
Fat accumulation is more common in women and fat loss 
in men. In one study, Caucasians exhibit more lipoatrophy, 
whereas non-Caucasians develop more lipohypertrophy.23 
Several polymorphisms were identified as being involved in 
the development or severity of lipodystrophy, whereas others 
seem to have a protective role.38–45
HIV infection can increase expression of antiadipogenic 
and proinflammatory genes and inhibit the expression of 
proadipogenic genes and genes coding for adiponectin 
and leptin.35 In multivariate analysis, advanced stage of 
HIV infection (established AIDS), longer duration of HIV 
infection, low nadir CD4 cell count, decrease in CD4 cell 
count, and high viral load have been identified as risk fac-
tors for lipodsytrophy.17,23,24,46–49 The role of hepatitis C 
virus coinfection in the development of lipodsytrophy is 
controversial.50,51
Different effects on adipose tissue have been described 
according to the family of ARV drugs. Moreover, among 
different members of an ARV family, the magnitude of these 
effects is very variable. Thymidine analogs and, especially, 
stavudine have been shown to be involved in the development 
of lipoatrophy.27,52–56 These molecules act essentially through 
a mitochondrial toxicity by inhibiting DNA polymerase γ.57–62 
In addition, thymidine analogs altered adipocyte functions, 
reduced lipid content, reduced adiponectin and leptin release, 
and in parallel, increased ROS production and monocyte 
chemoattractant protein-1 and interleukin-6 release.63 The 
association of oxidative stress and lipodystrophy has been 
confirmed in a recent clinical study in HIV-infected men.64 
Protease inhibitors (PIs) are more closely associated with 
lipoaccumulation but may also participate in lipoatrophy.65,66 
PIs inhibit adipocyte differentiation.67,68 They may also exert 
a deleterious effect on mitochondrial function.69 Moreover, 
some PIs inhibit the glucose transporter isoform Glut4 at 
physiological concentrations.70,71 Finally, some PIs alter adi-
pokine secretion and lipid content through ROS production 
in human subcutaneous adipocytes.63 An additive, even syn-
ergistic, toxicity of nucleoside reverse transcriptase inhibitors 
(NRTIs) and PIs on peripheral fat tissue has been observed 
in vivo.33 The role of non nucleoside reverse transcriptase 
inhibitors (NNRTIs) on adipose tissue is unclear. In a recent 
comparative prospective study, the incidence of lipoatrophy 
was higher among patients receiving efavirenz (EFV) than 
in those receiving PIs.72 Regarding the most recent drugs 
(fusion inhibitors, integrase inhibitors, and CCR5 chemokine 
receptor agonists), they do not seem to exert a deleterious 
effect on adipose tissue.
Diagnosis
In most studies, the diagnosis of lipodystrophy is based on clini-
cal grounds that include signs and symptoms (Table 1).34,35,73,74
The diagnosis of lipoatrophy is currently accepted if 
weight loss (due to loss of body fat) located on the face 
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lower limbs and/or upper limbs is reported by the patient 
(or his/her entourage) and confirmed by the physician.17,75,76 
However, the finding of fat loss by the patient and the physi-
cian is already witnessing an advanced lipoatrophy. Fat loss 
in the limbs often results in an apparent hypertrophy of the 
venous system sometimes described as “venomegaly”.
The diagnosis of lipohypertrophy is also based on the 
patients’ complaints confirmed by clinical examination by 
the physician. Clinical features may include abdominal girth, 
dorsocervical fat pad (buffalo neck), supraclavicular fat pad, 
anterior neck fat accumulation, chest enlargement (gyneco-
mastia or lipomastia), hypertrophy of the parotid areas, supra-
pubic fat accumulation, and single or multiple lipomata.75,76
In some studies, anthropometric measurements are used 
as diagnostic criteria.
Lipoatrophy may be evaluated by measuring bicipital, 
tricipital, subscapular, and suprailiac folds.77
Waist and hip circumferences and waist-to-hip ratios 
have been used to evaluate fat accumulation. Waist-to-hip 
ratios greater than 0.95 in men and 0.85 or 0.90 in women 
are indicators of lipohypertrophy.34,78
The European AIDS Clinical Society recommends moni-
toring for changes in body composition of HIV patients by 
using body mass index, waist circumference, waist-to-hip 
ratio, and clinical lipodystrophy in all patients at HIV diag-
nosis, before starting highly active antiretroviral therapy 
(HAART), and annually thereafter.79
The most reliable means to assess lipodystrophy are 
undoubtedly imaging studies. However, they are not always 
readily available in routine and are sometimes expensive. 
Most of them could be reserved for research studies.
Dual-energy X-ray absorptiometry (DXA), ultrasonog-
raphy, computed tomography (CT), and magnetic reso-
nance imaging (MRI) have all been used for the objective 
measurement of the fat composition of particular body 
regions or given compartments in patients with lipodystrophy 
syndrome.
DXA can detect fat modifications earlier than clinical 
assessment,80 although a significant negative correlation 
exists between DXA-measured limb fat and lipoatrophy 
scores generated by either the patients or the physicians.81
Fat mass ratio (equals to ratio of percentage of trunk fat 
mass to the percentage of lower limbs fat mass) measured 
by DXA may be useful for detecting early (subclinical) 
lipodystrophy and its evolution.80,82,83
In recent studies, lipoatrophy was defined as a reduction 
of 20% or more in limb fat measured by DXA. However, 
there is a weak correlation between lipoatrophy, using this 
definition, and clinical lipoatrophy as perceived by the 
patient. Indeed, loss of body fat of at least 35% is required 
for it to become clinically evident.84
Some authors have reported a good correlation between 
subcutaneous fat measurement using ultrasonography and 
other methods of diagnosing lipoatrophy.85,86
CT and MRI are particularly useful for measuring the 
intra-abdominal fat mass.85–87
Treatment
Conventional and old strategies
ARV switch strategies
Lipoatrophy
As PIs have been first suspected to be the only agents 
responsible for lipoatrophy, the first therapeutic strategy for 
HIV-associated lipodystrophy proposed was the substitution 
of the PI with an NNRTI (Table 2). Unfortunately, this 
strategy did not lead to significant gain in limb fat.88–90
The association of thymidine analog NRTIs with 
lipoatrophy was shown in subsequent in vitro and in vivo 
studies. Therefore, it was logical to explore the efficacy 
of switching from these drugs to alternative NRTIs or 
NRTIs-  sparing regimens in order to try to reverse lipoatrophy. 
A modest but significant gain of limb fat has been reported 
in several studies.72,91–98 However, this gain was not clinically 
relevant in most studies, probably, because the duration of 
follow-up was too short. Anyway, it was demonstrated that 
lipoatrophy was (at least partially) reversible when switching 
from thymidine analogs to other NRTIs. The speed and the 
Table 1 Diagnostic methods of lipodystrophy
Clinical assessment by the patient and the physician
  Fat loss (lipoatrophy) 
      Face: sunken, hollow temples, sunken eyes, prominent zygomatic arch
    extremities: prominent veins, skinny or muscular appearance 
  Fat accumulation (lipohypertrophy) 
    Increased abdominal girth 
    Supraclavicular fat pad 
    Dorsocervical fat pad 
    Anterior neck fat accumulation 
    Chest enlargement (gynecomastia and lipomastia) 
    Hypertrophy of the parotid areas 
    Suprapubic fat accumulation 
    Single or multiple lipomata
Anthropometric measurements 
    Bicipital, tricipital, subscapular, and suprailiac folds 
waist-to-hip ratio
Imaging methods 
    Dual-energy X-ray absorptiometry 
echography 
Computed tomography 
Magnetic resonanceHIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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magnitude of the recovery depend on how early the switch 
is made.82
Lipohypertrophy
There is no published evidence that NRTI switching leads to 
significant changes in trunk or visceral fat, and consequently, 
to an improvement of lipohypertrophy.
There are conflicting results concerning the effects on fat 
accumulation of switching from PI to EFV or nevirapine or aba-
cavir. An improvement of lipohypertrophy, if any, appears to be 
weak. Most studies exploring this strategy are summarized by 
Baril et al.34 The results of PI switch studies (in which a boosted 
PI is replaced by atzanavir/ritonavir) are divergent.99,100
Lifestyle modifications
Lipoatrophy
Exercise and diet may induce modifications of the appear-
ance of limbs by a gain of muscular mass. However, there 
are no data showing any substantial gain in peripheral fat by 
modifying lifestyle. Consequently, changes in lifestyle are not 
part of the measures recommended to improve lipoatrophy.
Lipohypertrophy
Several studies have documented effects of diet and exer-
cise on central fat accumulation.101–103 Regular exercises 
can reduce intra-abdominal lipoaccumulation and improve 
muscle strength, lean mass, and blood lipids. However, it can 
aggravate lipoatrophy. A diet, rich in fiber, adequate in energy 
and protein can reduce fat depot, but a beneficial effect on 
insulin resistance is not always reported.104,105
Pharmacologic interventions
Lipoatrophy
Adipose cell function in patients with lipoatrophy is partially 
restored by the peroxisome proliferator-activated receptors-γ 
agonists, thiazolidinediones.106 Thus, it is hypothesized that 
treatment with thiazolidinediones could improve, at least par-
tially, the subcutaneous lipoatrophy. A recent meta-analysis 
Table 2 Therapeutic strategies for HIV-associated lipodystrophy
Type of treatment Effects of treatment on lipodystrophy
Lipohypertrophy Lipoatrophy
Switch strategy Not proved to be effective (further  
studies needed with new ARV families)
May be beneficial, particularly if early intervention
Diet and exercise May reduce visceral adiposity May worsen subcutaneous fat loss
Surgical and corrective  
cosmetic measures
To be strongly considered if excess  
of abdominal subcutaneous fat. 
May be the best therapeutic option  
for breast enlargement, buffalo hump,  
lipomas, and various localized fat deposits
May be the only effective option and give immediate 
results (facial lipoatrophy)
Pharmacologic treatments – –
Thiazolidinediones – –
  Rosiglitazone
  Pioglitezone
No effect, despite improvement of peripheral 
insulin sensitivity
No effect, despite improvement of peripheral insulin 
sensitivity
No effect Small but significant improvement of limb fat atrophy 
as measured by DXA, no clinical benefits perceived 
by the patients (after 48 wk of treatment)
Statins – –
  Pravastatin No effect May decrease subcutaneous fat
Metformin (Kohli R HIV Med 2007) May reduce visceral adipose tissue  
and total adipose fat
May induce additional loss in limb fat
Recombinant human growth hormone 
(somatotropin)
Decreases visceral adipose tissue May worsen subcutaneous lipoatrophy
Growth hormone-releasing factor Decreases visceral adipose tissue No effect on lipoatrophy
Testosterone No effect No effect
Uridine May increase visceral fat Small and not sustained improvement in limb fat
Leptin Decrease visceral fat No effect
Acetyl-l-carnitine No effect May increase leg fat
Adiponectin and adiponectin receptors Investigational
TNF-α antagonists Not studied and not recommended in HIV-infected patients
IGF-1/BP-3 No effect No effect
Abbreviations: HIV, human immunodeficiency virus; ARV, antiretroviral; DXA, dual-energy X-ray absorptiometry; TNF-α, tumor necrosis factor-α; IGF-1/BP-3, insulin-like 
growth Factor-1/binding protein-3.HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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of clinical trials of thiazolidinedione therapy for HIV 
lipoatrophy concluded that patients receiving pioglitazone 
had significantly higher limb fat mass gain compared with 
those receiving placebo, whereas patients on rosiglitazone 
did not. Interestingly, the effectiveness of glitazones did not 
vary according to whether the patients were receiving thymi-
dine analogs.107,108 Moreover, glitazones can decrease bone 
formation and accelerate bone loss. This could be particularly 
deleterious in HIV-infected patients in whom a preexisting 
osteopenia is frequently observed. The effects of pioglitazone 
are detailed in section “New and emerging agents”.
There are few studies exploring the effects of statins on 
body composition in HIV-infected patients. Mallon et al109 
showed that apart from lowering lipids, pravastatin can also 
increase subcutaneous fat and limb fat. Improvement of 
lipohypertrophy by pravastatin treatment was not confirmed 
by Macallan et al110 and Calmy et al.111
Whether uridine is a promising or disappointing treatment 
of lipoatrophy will be discussed later.
Lipohypertrophy112
Insulin sensitizers such as metformin have been used to 
treat HIV lipodystrophy in which fat accumulation and 
insulin resistance are prominent factors. Some studies 
indicated that treatment with metformin can reduce visceral 
adipose tissue, total adipose fat, waist circumference, and/
or waist-to-hip ratio in HIV-infected nondiabetic patients 
with lipohypertrophy.113,114 However, other studies did not 
show any change in waist-to-hip ratio, and rather, worryingly 
additional loss in limb fat.115–117
Statins have been used for lowering lipid levels in 
HIV-infected patients. However, there are no data support-
ing their use in the treatment of visceral fat and trunk fat 
accumulation.109
Several clinical trials demonstrated a significant loss of 
visceral fat content in HIV-infected patients treated with recom-
binant human growth hormone (rhGH; somatotropin).118–122 
However, an increase in insulin resistance is often noted, which 
limits, of course, the use of this drug in this indication.
Although in epidemiological studies, serum total and free 
testosterone concentrations have been inversely correlated 
with intra-abdominal fat mass, and testosterone adminis-
tration to middle-aged men is associated with decreased 
visceral fat, there are no convincing data on the beneficial 
effects of testosterone in HIV-infected patients.123 In a small 
study, transdermal administration of testosterone failed to 
demonstrate a decrease in visceral fat in HIV-infected men 
with abdominal obesity.124
Surgical or cosmetic corrective treatments
Lipoatrophy
Various injectable fillers have been used to treat facial 
lipoatrophy.125 Permanent fillers are synthetic materials that 
are designed to provide a sustained filling of the space vacated 
by the loss of facial fat. They include purified silicone oil, 
polymethylmethacrylate, polyalkylamide, and polytetra-
flurorethylene. There are limited data in HIV-associated 
lipoatrophy. None of these products are approved by the 
Food and Drug Administration (FDA).
Temporary fillers need to be reinjected at regular inter-
vals. To date, two products are approved by the FDA in the 
treatment of HIV-associated facial lipoatrophy: poly-l-lactic 
acid (PLLA; Sculptra or New-FillTM; sanofi-aventis, Bridge-
water, NJ) and calcium hydroxylapatite (RadiesseTM; Bioform 
Medical Inc., San Mateo, CA). Several (small) studies have 
been performed to assess their effectiveness.126–132 HIV-in-
fected patients treated with PLLA or calcium hydroxylapatite 
for facial lipoatrophy have reported more satisfaction with 
their physical appearance and improvement in their quality 
of life.125
Use of autologous fat implantation can be a suitable 
method to correct facial lipoatrophy in patients who have 
sites with sufficient subcutaneous fat to donate.133–138 Unfortu-
nately, available donor sites are lacking in most HIV-infected 
patients suffering from lipoatrophy.
Other temporary fillers including bovine or human 
collagen and hyaluronic acid have been used with limited 
experience in HIV-infected patients with facial lipoatrophy, 
and are not approved by the FDA.139
Finally, silicone gluteal prosthesis can be proposed for 
patients with fat loss in the buttocks, who complain of painful 
sitting down or who present trophic cutaneous disorders.140
Lipohypertrophy
Liposuction has been used successfully to treat dorsocervical 
fat accumulation (buffalo hump), gynecomastia, or increased 
abdominal contour.141–144
Surgical breast reduction (mammoplasty) is an alternative 
for women with breast enlargement. Other surgical resec-
tions could be indicated for lipomas and various localized 
fat deposits.145
New and emerging agents
Treatment of lipoatrophy
Pioglitazone
The effects of pioglitazone on lipoatrophy have been 
briefly described in “Conventional and old strategies”. HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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However, among the glitazones, the newest and most 
promising data concern pioglitazone than rosiglitazone.146 
Therefore, these results are detailed here. Thus, in a recent 
study, pioglitazone 30-mg daily (n = 64) was compared with 
placebo (n = 66) in patients with lipodsytrophy, changes in 
limb fat between weeks 0 and 48 were measured using DXA. 
Subcutaneous and visceral fat was measured using single-
slice CT. Pioglitazone was associated with an increase in limb 
fat of 0.38 kg vs 0.05 kg of placebo (P = 0.05) at 48 weeks. 
Among patients not receiving stavudine (n = 48 vs 46), the 
increase was 0.45 kg in the pioglitazone group vs 0.04 kg in 
the placebo group (P = 0.013), whereas among those receiv-
ing stavudine (n = 16 vs 20), the increase was 0.17 kg in the 
pioglitazone group vs 0.07 kg in the placebo group (P = 0.40). 
Piogitazone was also associated with an increase in thigh cir-
cumference (1.4 cm vs 0.2 cm; P = 0.017). However, all these 
changes in body composition were not sufficient to be detected 
clinically by patients. The differences observed between groups 
in changes in visceral adipose tissue (5.3 cm2 vs 7.7 cm2) or 
abdominal subcutaneous tissue (16.3 cm2 vs 7.8 cm2) were not 
statistically significant. The lipid profile was not significantly 
different at week 48 except for levels of high-density lipopro-
tein (HDL) cholesterol, which was improved in the pioglita-
zone group (+0.08 mmol/L vs −0.08; P = 0.005). However, 
despite significant changes in limb fat, there were no statistical 
significant differences in clinical manifestations. Pioglitazone, 
unlike rosiglitazone, is metabolized by cytochrome P450 3A4 
enzymes and thus has potential for pharmacokinetic interac-
tions with PIs. A recent meta-analysis performed by SH Sheth 
and RJ Larson108 concluded that rosiglitazone should not be 
used in HIV-associated lipodystrophy syndrome, pioglitazone 
may be safer, and any benefits appear small.
Uridine
In vitro studies suggest that the compound uridine, a 
pyrimidine precursor, can reverse mitochondrial toxicity 
induced by ARV pyrimidine analogs such as zalcitabine and 
stavudine with cell restoration, notably in adipose tissue. 
NucleomaxX TM (Pharma Trade Healthcare AB, Spänga, 
Sweden) is a sugar cane-derived dietary supplement that 
increases uridine levels. The preliminary results of small 
studies in HIV patients receiving stavudine or zidovudine-
containing ARV therapy show that a dietary supplement 
with NucleomaxX (36 g, twice a day) is well tolerated and 
improves lipoatrophy scores generated by patients and physi-
cian or increases limb fat.147,148 Unfortunately, it also increases 
visceral fat. This can be particularly annoying in patients 
who have already a mixed lipodystrophy.147 Furthermore, 
in contrast to in vitro data, NucleomaxX supplementation 
did not lead to changes in fat or blood mitochondrial DNA 
levels.148 These promising data on lipoatrophy improvement 
are not fully confirmed in a larger prospective, randomized, 
placebo-controlled multicenter trial (ACTG study A5229).149 
In this study, the results demonstrate that in HIV lipoatro-
phy, despite a small increase in limb fat after 24 weeks with 
as-treated analysis, the effect was not sustained through 48 
weeks of uridine.111,149
Leptin
Leptin is a protein hormone that plays a key role in regulating 
energy intake and energy expenditure, including appetite and 
metabolism. It is one of the most important adipose-derived 
hormones. It has peripheral effects on skeletal muscle, liver, 
pancreas, adipose tissue, and other cell types where it acts to 
decrease anabolic pathways (such as glucose, lipid, and pro-
tein synthesis) and increase catabolic pathways (glucose and 
lipid utilization). Leptin therapy has been used successfully 
in patients with congenital and acquired non-HIV–related 
lipodystrophy.150,151 In HIV-infected patients on HAART, leptin 
levels have been found to positively correlate with body mass. 
The rationale for using leptin to treat HIV-  associated lipoatrophy 
is based on the results of cross-sectional studies showing that 
levels of both leptin and adiponectin are decreased in HIV-lipoa-
trophic patients and are inversely correlated with dyslipidemia 
and insulin resistance.152,153 In fact, in HIV lipodystrophy, leptin 
administration is well tolerated, improves lipid profiles and insu-
lin resistance, and decreases visceral fat, but has no significant 
effect on subcutaneous or peripheral fat deposition.154–156
Acetyl-l-carnitine
l-carnitine is a nonessential micronutrient that regulates fatty 
acid transport into the mitochondrial matrix for metabolism 
via β-oxidation. HIV-infected individuals on ARV therapy 
may become deficient in this cofactor, limiting mitochon-
drial fat metabolism. One small recent study showed that 
HIV-infected patients with lipodystrophy had an increase in 
the percentage of leg fat after a treatment of 8 months with 
l-carnitine (2 g/d).157
Treatment for lipohypertrophy
Human growth hormone-releasing factor
Human growth hormone-releasing factor (GHRH) analogs 
induce a more physiological release of GH, with normal 
feedback inhibition, and are, therefore, potentially less 
toxic than rhGH, previously used in the treatment of fat 
accumulation.HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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Compared with placebo, injectable GHRH analogs (Geref 
or GHRH 1–29 and Tesamorelin or TH9507) increase lean 
body mass, decrease visceral and trunk fat, and improve the 
ratio of visceral fat to lower extremity fat.158–160 They have 
minimal effect on subcutaneous adipose tissue and did not alter 
glucose metabolism, in contrast to rhGH (see above).158–160 
Tesamorelin also improves lipid profiles; triglyceride levels 
and the ratio of total to HDL cholesterol decrease.160 The 
benefit of tesamorelin is similar in men and women and is 
not affected by ARV therapy. Main adverse events leading to 
discontinuation are related to injection-site reactions. Serious 
adverse events are not significantly higher in the tesamorelin 
arm (5%) than in the placebo arm (2%).159 Use of GHRH 
analogs require long-term treatment for continued benefit, 
as patients who stop treatment regain their visceral adipose 
tissue.160 Finally, the cost of this treatment is very high, so its 
access could be restricted to few patients.
Leptin
It has been shown that leptin therapy can decrease visceral 
fat without significant effect on subcutaneous or peripheral 
fat deposition156 (see “Treatment of lipoatrophy”).
Adiponectin
Adiponectin is a cytokine exclusively secreted from adipose 
tissue. It modulates a number of metabolic processes, 
including glucose regulation and fatty acid catabolism. 
Adiponectin acts via two receptors; AdipoR1 located in 
skeletal muscle and AdipoR2 located in the liver.33 The 
level of adiponectin is reduced in visceral obesity.161 
HIV-associated lipodystrophy is associated with low plasma 
adiponectin levels and low expression of adiponectin in 
adipose tissue.162–164 Thus, adiponectin and its receptors are 
attractive future targets for drug development in the treatment 
of HIV-related lipohypertrophy.165
Tumor necrosis factor-α antagonists
Tumor necrosis factor-α (TNF-α) is a proinflammatory 
cytokine overexpressed in fat tissue of obese patients, espe-
cially in subcutaneous fat and even further in omental fat.166 
TNF-α may be the link between visceral obesity and devel-
opment of insulin resistance, dyslipidemia, type 2 diabetes, 
and cardiovascular diseases.33 TNF-α also induces apoptosis, 
which might underline the lipoatrophy caused by NRTIs.167
It has been suggested that TNF-α-238 promoter region 
gene polymorphism increases the risk of   developing 
ARV-related lipodystrophy.168 Nevertheless, the use of TNF-α 
antagonists has been disappointing in obese non-HIV patients 
with type 2 diabetes mellitus.169 Moreover, there is no trial 
assessing the benefit of TNF-α antagonists in the treatment 
of HIV-associated lipodystrophy, given the risks of causing 
opportunistic infections.
Insulin-like growth factor-1/binding protein-3
To date, we have found only one small, open-label study on the 
use of insulin-like growth factor-1/binding protein-3 (IGF-1/
BP-3) therapy in HIV-infected patients with visceral fat accu-
mulation and insulin resistance. Upon treatment with IGF-1/
BP-3, insulin resistance and trunk fat decrease, whereas no 
decrease in visceral adipose tissue is observed.170 These results 
are not encouraging for the design of future studies with this 
compound in the field of HIV-associated lipodystrophy.
Conclusion
The best strategy to prevent HIV-associated lipodystrophy 
is to avoid, if possible, ARV therapies, which are known 
to be associated with fat modifications. Some NRTIs, 
especially thymidine analogs, are associated with lipoat-
rophy and must be avoided to prevent peripheral fat loss. 
Concerning lipohypertrophy, there is no proven strategy to 
prevent it. Not only PIs but also EFV have been implicated 
in the development of lipohypertrophy. Some new ARVs 
(integrase inhibitors and CCR5 coreceptor antagonists) 
could induce fewer changes in fat distribution and deserve 
further attention.
If lipodystrophy is detected at an early stage, a switch of 
ARV drugs makes sense to avoid worsening. Early use of 
pioglitazone must be considered in patients with lipoatrophy. 
In patients with fat accumulation, diet, exercise, and met-
formin may be beneficial; however, in patients with mixed 
lipodystrophy, they may worsen lipoatrophy.
If lipodystrophy is supported at a late stage, a switch of 
ARV therapy should still be warranted particularly in cases 
of lipoatrophy. Surgical or cosmetic corrective treatments are 
often required. Additional pharmacologic interventions such 
as the use of pravastatin and pioglitazone should be consid-
ered for the treatment of lipoatrophy. For patients who have 
only lipohypertrophy, exercise and diet may be proposed, as 
well as the administration of metformin or rhGH. Finally, for 
patients who have mixed form of lipodystrophy, promising 
pharmacologic treatments, which may improve lipohyper-
trophy without worsening lipoatrophy, include GHRH and 
leptin. If lipoatrophy is predominant, l-carnitine could be 
beneficial without increasing visceral fat accumulation. 
Adiponectin and its receptors are also attractive targets for 
the treatment of HIV-related lipodystrophy.HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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